公开(公告)号：US20210322428A1

公开(公告)日：2021-10-21

申请号：US17285161

申请日：2019-10-17

Applicant: YUHAN CORPORATION

Inventor： Seongkyu KIM ,  Deokkyu LEE ,  Soo-Won KIM ,  Jun-Mo YANG ,  Yoong-Sik PARK

IPC: A61K31/5377 ,  A61K9/00 ,  A61K9/20

Abstract: The present disclosure provides a pharmaceutical composition for oral administration comprising: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide (Lazertinib) or its pharmaceutically acceptable salt as an active ingredient; and a combination of microcrystalline cellulose and mannitol as a diluent.

公开(公告)号：US20180147150A1

公开(公告)日：2018-05-31

申请号：US15882390

申请日：2018-01-29

Applicant: YUHAN CORPORATION

Inventor： Jeong-Hoon WOO ,  Woon-Sook NA ,  Yang-Soo JEONG ,  Chang-Keun HYUN ,  Yoong-Sik PARK

IPC: A61K9/20 ,  A61K31/197 ,  A61K9/00 ,  A61P25/08

CPC classification number: A61K9/2031 ,  A61K9/0002 ,  A61K9/0065 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095 ,  A61K31/197 ,  A61P25/08

Abstract: Provided is a sustained release tablet having two-phase release-controlling system, which consists of a first release-controlling phase including pregabalin or its salt and hydroxypropyl methylcellulose; and a second release-controlling phase including polyethylene oxide as a swelling polymer, the first release-controlling phase being homogeneously dispersed in the second release-controlling phase.